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Background 
• Data was obtained from the Women’s Health Initiative database. The 
Women’s Health Initiative (WHI) enrolled a total of 161,808 women, with 
93,676 participants in an observational study (WHI-OS) and 68,132 
participants in clinical trials (WHI-CT), between 1993 and 1998 with an 
average of 7.6 years of follow-up until March 31, 2005. At baseline, the 
mean age was 63 years and about 18% of the women were from ethnic 
minority groups. Both multiple sclerosis and osteoporosis were diagnoses 
identified at baseline and in follow-up in the WHI cohort. 
• The sample included 449 women who reported an MS diagnosis at 
baseline and 152,432 women without MS who comprised a control group. 
Baseline measures of self-reported osteoporosis, age, smoking status, 
steroid and anti-inflammatory use, and supplementary as well as dietary 
calcium and vitamin D were analyzed using multivariate linear regression. 
• For both the MS and control groups, participants with osteoporosis at 
baseline were removed to monitor the time to incident osteoporosis. 
• Variables having significant associations with MS and osteoporosis were 
monitored in follow-up and proportional hazards modeling was performed  
to adjust for relevant covariates over time and potential impact on incident 
cases of osteoporosis. 
• Latency to incident osteoporosis and use of osteoporosis-related 
medications was also compared between MS and non-MS participants 
using either a T test or a Wilcoxian Ranksum test. The type of intervention 
for treating osteoporosis in both cohorts was also studied using a 2 x 2 
contingency table analysis with a Fisher’s exact test. 
• Multiple sclerosis (MS) is an autoimmune progressive neurological disease 
that leads to early disability of young adults. Reduced mobility and frequent 
falls, secondary to spasticity and ataxia, increase the risk for osteoporosis. 
In fact, fractures are a major cause of morbidity and mortality in patients 
suffering from MS.1,2 Moreover, many patients with MS and low bone mass 
or previous fractures are not taking supplemental calcium or vitamin D.3 
• Several studies have examined the incidence of reduced bone mineral 
density (BMD) amongst people with MS, and the majority providing evidence 
that BMD is significantly reduced in MS patients. The most significant risk 
factors appear to arise from the chronic disease process of MS and not from 
glucocorticoid use.3-7 However, the temporal relationship between these two 
conditions has not been previously studied.  
• Fortunately, data from the Women's Health Initiative provides a unique 
opportunity to examine the development of osteoporosis over time and its 
relationship to MS. The WHI population is ideal to study because patients 
will be more likely to reflect the longstanding MS that affects mostly women. 
• From longitudinal data (baseline and follow-up studies), the association 
between MS and osteoporosis can be examined over time and refined by 
considering the contributions of additional pharmacologic and lifestyle 
variables. Latency and type of treatment for osteoporosis in MS and non-MS 
populations can provide insight for clinical recommendations regarding an 
at-risk population. 
 
• Report of MS at baseline is significantly associated with report of 
osteoporosis at baseline (p<0.0001). 
• Associations were noted between MS and younger 
age, smoking history and less supplemental calcium. 
• Multivariate linear regression demonstrated a four-
fold risk of baseline MS in association with 
osteoporosis when adjusting for age, smoking 
status, steroids and anti-inflammatory use, as well 
as dietary and supplemental  calcium and vitamin D.  
• WHI follow-up data demonstrated strong associations between: 
• MS and age, education, BMI, smoking, steroid use, 
dietary calcium and vitamin D, hormone use, 
moderate and recreational exercise, and 
menopausal age. 
• Osteoporosis and age, education, ethnicity, BMI, 
smoking, steroid and anti-inflammatory use, dietary 
and supplemental calcium and vitamin D, hormone 
use, and recreational exercise. 
• However, when adjusting for these associations in proportional 
hazards modeling, MS at baseline was not significantly related to 
the report of osteoporosis at the end of the WHI study (p=0.88). 
• Osteoporosis in the MS and non-MS populations presented with 
similar latencies and treatment for both groups was similar in terms 
of timing and type of intervention. 
• The higher prevalence of osteoporosis at baseline suggests MS 
may significantly increase the risk of osteoporosis in premenopausal 
women while pharmacologic and lifestyle variables have a more 
significant role in post-menopausal women. 
• Postmenopausal women with MS may have less 
active inflammation and more slowly progressive 
accumulation of disability due to a proved neuro-
degenerative process. With the three-fold risk noted 
in the WHI sample, the impact of MS on developing 
osteoporosis may be a function of early-stage MS, 
which was not prevalent in the WHI cohort. 
• Additional prospective studies should examine bone 
changes and incident osteoporosis in a younger MS 
population to determine if early detection and 
treatment could ultimately prevent the increased risk 
of osteoporosis seen in women with MS in this study. 
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Table 1: Baseline characteristics of participants with and 
without MS. Women with MS are nearly three times as likely to 
report osteoporosis, are younger, are more likely to have smoked, 
and consume less supplemental calcium.   
Table 2: Multivariate logistic regression model for self-report 
of an osteoporosis diagnosis. A cross-sectional logistic 
regression of baseline data was performed to determine factors 
positively associated with an osteoporosis diagnosis . While this 
analysis cannot determine temporal ordering of predictors and 
osteoporosis, significant associations were observed with age, 
smoking, steroid use, anti-inflammatory use, supplemental 
calcium and vitamin D as well as dietary vitamin D. After 
adjusting for confounders, self-reported MS diagnosis was more 
strongly associated with self-reported osteoporosis diagnosis. 
Figure 1: Activity level according to age from the North American 
Research Committee on Multiple Sclerosis (adapted figure). 
Figure 2A and 2B: Latency and treatment of osteoporosis.  
A) No significant difference was observed between MS and non-MS 
participants in time to incident osteoporosis. Time to intervention 
with bisphosphonates, selective estrogen receptor modulators 
(SERMs), calcium, or hormones was similar between cohorts.  
B) For management of osteoporosis in addition to calcium and 
vitamin D, most participants in both groups were on a 
bisphosphonate (alendronate > risendronate) and a SERM 
(raloxifene > tamoxifen). 
Table 4: Proportional hazards model of MS and follow-up 
variables on incident osteoporosis. When adjusting for 
associations between follow-up variables and MS and/or 
osteoporosis, there is no significantly increased risk of 
developing osteoporosis for those with MS at baseline 
compared to those without. 
% (N) of MS / no-MS group 
Characteristic MS (N=449) No MS (N=152432) p-value 
Self-report of osteoporosis diagnosis 20.94 (94) 7.7 (11762) <0.0001 
Age stratum at randomization or enrollment: <0.0001 
  50 – 54 21.6 (97) 12.9 (19669) 
  55 – 59 26.1 (117) 19.5 (29687) 
  60 – 69 40.8 (183) 45.1 (68520) 
  70 – 79 11.6 (52) 22.4 (34107) 
Smoking: <0.0001 
  Never 38.8 (172) 51.0 (76555) 
  Past 51.9 (230) 42.1 (63201) 
  Current 9.3 (41) 6.9 (10371) 
Steroid use 0.9 (4) 0.9 (1940) 0.8020 
Anti-inflammatory use 20.9 (94) 19.1 (29044) 0.3361 
Supplemental calcium: 0.0331 
  None 44.3 (199) 43.6 (66199) 
  1st quartile 16.7 (75) 16.8 (25478) 
  2nd quartile 15.4 (69) 11.8 (18001) 
  3rd quartile 9.6 (43) 13.8 (20935) 
  4th quartile 14.0 (63) 14.1 (21369) 
Dietary calcium: 0.7445 
  1st quartile 25.7 (115) 25.0 (37935) 
  2nd quartile 26.1 (117) 25.0 (37932) 
  3rd quartile 25.5 (114) 15.0 (37935) 
  4th quartile 22.8 (102) 25.0 (37947) 
Supplemental Vit D: 0.5219 
  None 53.9 (242) 51.4 (78052) 
  < 10 mcg 8.7 (39) 10.2 (15503) 
  10 mcg 28.7 (129)   28.5 (43368) 
  >10 mcg 8.7 (39) 9.9 (15059) 
Dietary Vit D: 0.1082 
  1st quartile 29.5 (132) 25.0 (37918) 
  2nd quartile 22.1 (99) 25.0 (27950) 
  3rd quartile 25.7 (115) 25.0 (37934) 
  4th quartile 22.8 (102) 25.0 (37947) 
Predictor: Adjusted odds ratio (95% CI) p-value 
Multiple sclerosis 4.14 (3.25, 5.27) <0.0001 
Age stratum: <0.0001 
  50 – 54 Reference 
  55 – 59 1.42 (1.28, 1.56) 
  60 – 69 2.67 (2.45, 2.91) 
  70 – 79 4.63 (4.24, 5.06) 
Smoking: 0.0003 
  Never Reference 
  Past 1.01 (0.97, 1.05) 
  Current 1.18 (1.09, 1.28) 
Steroid use 2.88 (2.51, 3.30) <0.0001 
Anti-inflammatory use 1.35 (1.29, 1.41) <0.0001 
Supplemental calcium: <0.0001 
  None Reference 
  1st quartile 1.05 (0.97, 1.13) 
  2nd quartile 1.56 (1.45, 1.68) 
  3rd quartile 2.15 (2.00, 2.31) 
  4th quartile 2.93 (2.75, 3.12) 
Dietary calcium: 0.0915 
Supplemental Vit D: <0.0001 
  None Reference 
  <10mcg 1.32 (1.23, 1.42) 
  10mcg 1.06 (1.00, 1.13) 
  >10mcg 1.37 (1.28, 1.47) 
Dietary Vit D: <0.0001 
  1st quartile Reference 
  2nd quartile 0.92 (0.87, 0.98) 
  3rd quartile 0.95 (0.89, 1.02) 
  4th quartile 1.10 (1.02, 1.19) 
Parameter Hazard 
Ratio 
95% Hazard Ratio  
Confidence Limits 
Reporting MS at baseline 1.166 0.936 1.452 
Hormones ever 1.012 0.987 1.039 
Education level 1.006 0.992 1.020 
Participant age 0.998 0.997 1.000 
BMI 1.001 0.999 1.003 
Dietary Calcium (mg) 1.000 0.985 1.016 
Dietary Vitamin D (mcg) 1.002 0.987 1.017 
Recreational activity (mins/wk) 0.998 0.988 1.009 
Smoked at least 100 cigarettes ever 0.994 0.971 1.018 
Taking steroids at year 3 visit 1.047 0.935 1.173 
Table 3. WHI study follow-up. Significant associations were 
found between variables and both MS and osteoporosis. 
Condition Variable(s) P-value 
MS and 
osteoporosis 
Age, educational level, smoking, BMI, recreational 
activity   
<0.05 
MS Moderate activity <0.05 
Hormones 0.10 
Menopausal age 0.06 
Steroid use 0.24 
Dietary calcium (mg) 0.11 
Dietary vitamin D (mcg) 0.06 
Osteoporosis Hormones, ethnicity, dietary and supplemental 
calcium and vitamin D, steroid and NSAID use 
<0.05 
B) 
A) 
